Noteworthy studies presented at the 3rd European Lung Cancer Conference

April 11th, 2012
Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.

Three studies have been indicated as noteworthy:

Abstract 164O

First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 166O

Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 77O

Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer

Proffered Paper session, Friday, April 20, 14:30-16:00, Room C

Provided by European Society for Medical Oncology

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Comet Siding Spring whizzes past Mars (Update)

A comet the size of a small mountain and about as solid as a pile of talcum powder whizzed past Mars on Sunday, dazzling space enthusiasts with the once-in-a-million-years encounter.

Viagra protects the heart beyond the bedroom

Viagra could be used as a safe treatment for heart disease, finds new research published today in the open access journal BMC Medicine. The study reveals that long-term daily treatment of Viagra can provide protection for th ...